Managing dyslipidaemia: evolving role of combination therapy

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Dyslipidemia is a key modifiable risk factor for coronary heart disease (CHD).
• Current lipid-modifying agents are effective, yet many patients do not achieve guideline-recommended lipid targets.
• This necessitates exploring new therapeutic strategies to optimize lipid profiles.

Purpose of the Study:

• To review the role of combination therapy in managing dyslipidemia.
• To highlight the importance of achieving target levels for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides.
• To discuss the growing trend towards more aggressive lipid-lowering strategies.

Main Methods:

• Literature review of studies on dyslipidemia management and combination therapy.
• Analysis of current treatment guidelines and their recommendations for lipid targets.
• Discussion of the clinical implications of targeting LDL-C, HDL-C, and triglycerides.

Main Results:

• Lowering LDL-C is proven effective in delaying clinical cardiovascular events.
• HDL-C and triglyceride levels significantly influence the risk of complications.
• Combination therapy is a viable strategy for patients failing to meet lipid targets on monotherapy.

Conclusions:

• Combination therapy is becoming more prevalent globally as guidelines advocate for more aggressive treatment to reach lower lipid goals.
• Addressing all lipid parameters (LDL-C, HDL-C, triglycerides) is essential for comprehensive cardiovascular risk reduction.
• Optimizing lipid management through combination regimens is critical for improving patient outcomes in coronary heart disease prevention.